Psilocybin May Boost Brain Training’s Effects in Older Adults — Here’s What the Trial Is Actually Testing

Bottom line: A Phase 2 trial is investigating whether psilocybin may be associated with enhanced effects of cognitive training on brain function in older adults, including those with mild cognitive impairment or early-stage Alzheimer’s disease.

A Phase 2 trial is exploring whether psilocybin, the active compound in magic mushrooms, can make cognitive training more effective for older adults. This study is not a miracle cure — it’s a scientific investigation into how the brain responds to a combination of mental exercise and a psychedelic compound.

What’s being tested

This trial is looking at whether psilocybin can enhance the brain’s ability to adapt and improve in older adults. The research includes individuals with mild cognitive impairment or early-stage Alzheimer’s disease, as well as healthy older adults. Scientists are examining how cognitive training, either alone or combined with psilocybin, might influence neuroplasticity — the brain’s ability to reorganize itself — and whether these interventions can support memory, attention, and thinking skills.

The design at a glance

This Phase 2 trial is currently recruiting participants and is funded by the National Institute on Aging (NIA). These studies typically evaluate whether an intervention is safe and effective in a larger group of people, while also collecting more data on side effects. Participants will undergo heart function tests, brain imaging, and cognitive assessments. Some will also take part in cognitive training exercises, with a subset receiving psilocybin as part of the trial. The study is designed to understand how cognitive stimulation and psilocybin might work together to support brain health.

Why it matters

If the trial finds that psilocybin enhances the benefits of cognitive training, it could offer a new way to support brain function in older adults. Alzheimer’s disease and age-related cognitive decline are major public health concerns, and any intervention that promotes neuroplasticity could help maintain independence and quality of life. This research could also open new doors for studying how psychedelics might be used in treating neurodegenerative diseases and mental health conditions.

What this does NOT mean yet

It’s important to emphasize that the trial is still in the recruitment phase and has not yet produced any results. Registering a clinical trial does not mean the intervention is proven, safe, or endorsed by health authorities. Many trials do not reach their goals, and the outcomes of this study are still unknown. This trial is asking a scientific question — not offering evidence of a benefit — and readers should not interpret the trial’s registration as a recommendation for psilocybin or cognitive training as a treatment for Alzheimer’s or cognitive decline.

How to follow it

To stay updated on the progress of this trial, visit the ClinicalTrials.gov record. The site will provide updates on participant recruitment, trial results, and other developments as they become available. Following the trial’s progress can help readers stay informed about emerging research at the intersection of psychedelics, cognitive training, and brain health.

Sources

https://clinicaltrials.gov/study/NCT07721467 (NCT07721467)

Educational Disclaimer

This article is for informational and educational purposes only. It is not medical advice, mental health advice, diagnosis, treatment guidance, or a recommendation to use any substance, supplement, therapy, or protocol.

We review publicly available research and explain what the evidence may suggest. Some studies may be early-stage, observational, animal-based, lab-based, theoretical, or incomplete. Always consult a qualified professional before making health-related decisions.

Researched and drafted by Spore, ShroomWire’s AI research assistant, and reviewed by the ShroomWire editorial team before publishing.

If you or someone you know is struggling, you are not alone. In the US, call or text 988 (Suicide & Crisis Lifeline). Elsewhere, contact your local emergency or crisis service.